Get the Stockscreener App
4.2168
1.64%
-0.0532
Revelation Biosciences Inc stock is traded at $4.2168, with a volume of 47,978.
It is down -1.64% in the last 24 hours and down -57.09% over the past month.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
See More
Previous Close:
$4.27
Open:
$4.3
24h Volume:
47,978
Relative Volume:
0.21
Market Cap:
$2.23M
Revenue:
-
Net Income/Loss:
$-15.52M
P/E Ratio:
-0.227
EPS:
-18.58
Net Cash Flow:
$-16.61M
1W Performance:
+11.41%
1M Performance:
-57.09%
6M Performance:
-75.23%
1Y Performance:
-89.83%
1-Day Range:
$4.02
$4.3499
1-Week Range:
$3.69
$4.60
52-Week Range:
$3.34
$69.44
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650-800-3717
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
4.20 | 2.23M | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.06 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.98 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revelation Biosciences Inc Stock (REVB) Latest News
Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL
Allergic Rhinitis Market to Show Remarkable Growth Trends from - openPR
Revelation Biosciences stock hits 52-week low at $0.28 - MSN
REVB Start 1B Trial and Announces Split - MSN
Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn
Stock market today: Revelation Biosciences -93.16%, MiNK Therapeutics -91.40% among biggest losers in early trading - Business Upturn
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Revelation Biosciences stock hits 52-week low at $0.28 By Investing.com - Investing.com Canada
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - BioSpace
Revelation Biosciences to effect 1-for-16 reverse stock split to regain Nasdaq compliance - MSN
Revelation Bio Announces 1:16 Reverse Split, Advances CKD Drug Trial to Phase 1b - StockTitan
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Marketscreener.com
Revelation Bio Launches Phase 1b Trial of Gemini for Advanced Chronic Kidney Disease Treatment - StockTitan
Florida Trader Among 4 Arrested for 7-Year-Long Insider Trading Scheme - NewsBreak
Revelation Biosciences (REVB) Price Target Increased by 242.79% to 40.04 - MSN
Broker, Traders Charged With $1M Insider Trading Scheme - Law360
Personal Finance - Business Wire
Several More Companies Propose Move From Delaware To Nevada - JD Supra
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025 - Business Wire
Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off - MSN
Nasdaq Grants Revelation Biosciences Inc. Continued Listing - BioSpace
Nasdaq grants Revelation Biosciences’ request for continued listing - MSN
Revelation Bio Secures Nasdaq Listing, Advances Kidney Disease Drug After FDA Green Light - StockTitan
Getty Images Rumored To Be In Merger Talks With Shutterstock: Retail Sees Potential Combination As ‘Win-Win’ Proposition - MSN
Stock market today: Neumora Therapeutics down by 81.14% while Rain Oncology surged by 676.86% in early trading - Business Upturn
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.97% - MSN
Revelation Biosciences stock hits 52-week low at $0.32 - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Revelation Biosciences files for secondary offering of common stock - MSN
Revelation Biosciences stock hits 52-week low at $0.42 - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.42 By Investing.com - Investing.com UK
Reviewing Emmaus Life Sciences (OTCMKTS:EMMA) and Revelation Biosciences (NASDAQ:REVB) - Defense World
Revelation Biosciences stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.7 - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com UK
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Revelation Biosciences Secures $4M Through Warrant Exercise, Issues New Warrants - StockTitan
FDA approves Revelation Biosciences' drug trial for CKD By Investing.com - Investing.com Nigeria
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
Revelation Biosciences Inc Stock (REVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):